Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PALI Palisade Bio Inc.

Trading 01-21 09:37:51 EST

1.82

-0.07

-3.69%

High1.89	Low1.81	Vol258.33K
Open1.89	D1 Closing1.89	Amplitude4.23%
Mkt Cap271.21M	Tradable Cap191.12M	Total Shares149.00M
T/O479.31K	T/O Rate0.25%	Tradable Shares105.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PALI","market":"US","secType":"STK","nameCN":"Palisade Bio Inc.","latestPrice":1.8202,"timestamp":1769006267385,"preClose":1.89,"halted":0,"volume":258330,"delay":0,"changeRate":-0.03693121693121686,"floatShares":105000000,"shares":149000000,"eps":-2.330592,"marketStatus":"Trading","change":-0.0698,"latestTime":"01-21 09:37:51 EST","open":1.89,"high":1.89,"low":1.81,"amount":479312.792739,"amplitude":0.042328,"askPrice":1.83,"askSize":520,"bidPrice":1.82,"bidSize":420,"shortable":3,"etf":0,"ttmEps":-2.330592,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1769029200000},"marketStatusCode":2,"adr":0,"listingDate":1188187200000,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.899,"preClose":1.89,"latestTime":"09:25 EST","volume":32015,"amount":60244.7673035,"timestamp":1769005542283,"change":0.009,"changeRate":0.004762,"amplitude":0.031746},"postHourTrading":{"tag":"盘后","latestPrice":1.89,"preClose":1.89,"latestTime":"19:56 EST","volume":278216,"amount":519406.5949,"timestamp":1768957014991,"change":0,"changeRate":0,"amplitude":0.063492},"volumeRatio":1.663019},"requestUrl":"/m/hq/s/PALI/tweets","defaultTab":"tweets","newsList":[{"id":"2603991752","title":"BUZZ-Palisade Bio rises; bowel disease drug set for global conference spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2603991752","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603991752?lang=en_us&edition=fundamental","pubTime":"2026-01-16 22:20","pubTimestamp":1768573247,"startTime":"0","endTime":"0","summary":"BUZZ-Palisade Bio rises; bowel disease drug set for global conference spotlight** Shares of drug developer Palisade Bio PALI.O rise 1.7% to $1.78 premarket ** Co says its experimental ulcerative colitis drug, PALI2108, is set to be featured at two major medical conferences next year** Ulcerative colitis is a chronic bowel disease that causes inflammation and bleeding in the colon** PALI says earlystage data shows all patients responded with no serious safety issues** Presentations are planned for the Crohn’s & Colitis Congress in Las Vegas and the European Crohn’s and Colitis Organisation Congress in Stockholm - PALI** Says it is preparing a larger 12week study and planning Crohn’s disease research** As of last close, stock up ~42% over the past year ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nL4N3YH160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","PALI"],"gpt_icon":0},{"id":"2603999873","title":"BRIEF-Palisade Bio Announces Two Abstracts Selected For Poster Presentations At Leading Global Inflammatory Bowel Disease Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2603999873","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603999873?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:31","pubTimestamp":1768570291,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Announces Two Abstracts Selected For Poster Presentations At Leading Global Inflammatory Bowel Disease ConferencesJan 16 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO ANNOUNCES T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUAC3YHLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2603815999","title":"Palisade Bio Unveils Positive Phase 1a Results for Gut-Targeted Ulcerative Colitis Drug PALI-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2603815999","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603815999?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:30","pubTimestamp":1768570224,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc. has announced that two abstracts featuring its lead program, PALI-2108, have been selected for poster presentations at two major international inflammatory bowel disease  conferences in early 2026. The presentations will highlight translational findings from a Phase 1a study of PALI-2108, a gut-targeted PDE4 inhibitor, focusing on its clinical, histologic, and biomarker effects in ulcerative colitis. The results will be presented at the Crohn's & Colitis Congress 2026 in Las Vegas on January 23, 2026, and at the 21st Congress of ECCO in Stockholm on February 20, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9V22nn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4585","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU0314104364.USD","IE00B64PRP62.GBP","PALI","BK4112","SG9999014039.USD","SG9999014021.USD","NDAQ","SG9999014013.SGD","LU2095319765.USD","BK4588","IE00B3QW5Z07.USD","BK4007","SG9999014005.SGD"],"gpt_icon":0},{"id":"2603965001","title":"Director Donald Allen Williams Acquires Common Shares of Palisade Bio Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2603965001","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603965001?lang=en_us&edition=fundamental","pubTime":"2026-01-14 10:43","pubTimestamp":1768358624,"startTime":"0","endTime":"0","summary":"Donald Allen Williams, a director of Palisade Bio Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL15BHWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Donald Allen Williams Acquires Common Shares of Palisade Bio Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2602338377","title":"Palisade Bio Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602338377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602338377?lang=en_us&edition=fundamental","pubTime":"2026-01-09 23:21","pubTimestamp":1767972060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PALI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2026 10:21 ET (15:21 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","PALI"],"gpt_icon":0},{"id":"2602376472","title":"B. Riley Initiates Palisade Bio at Buy With $7 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376472","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376472?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:21","pubTimestamp":1767964892,"startTime":"0","endTime":"0","summary":"Palisade Bio (PALI) has an average rating of buy and mean price target of $13.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2602376386","title":"Palisade Bio Inc : B. Riley Initiates Coverage With Buy Rating; Target Price $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376386","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376386?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:04","pubTimestamp":1767963899,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3YA1JX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2601313578","title":"Palisade Bio Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2601313578","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601313578?lang=en_us&edition=fundamental","pubTime":"2026-01-06 02:46","pubTimestamp":1767638760,"startTime":"0","endTime":"0","summary":"Palisade Bio, Inc.  is currently at $2.11, down $0.39 or 15.6%. --Would be lowest close since Dec. 23, 2025, when it closed at $2.09. --On pace for largest percent decrease since Dec. 13, 2024, when it fell 25%. --Down 100% from its all-time closing high of $5452199.50 on April 9, 2014. --Down 15.6% from its 52-week closing high of $2.50 on Jan. 2, 2026. --Up 291.47% from its 52-week closing low of $0.54 on Sept. 10, 2025. --Traded as low as $2.09; lowest intraday level since Dec. 24, 2025, when it hit $2.06. --Down 16.4% at today's intraday low; largest intraday percent decrease since July 24, 2025, when it fell as much as 21.31%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2595719592","title":"Palisade Bio Initiated at Buy by Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2595719592","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595719592?lang=en_us&edition=fundamental","pubTime":"2025-12-31 01:17","pubTimestamp":1767115020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PALI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 30, 2025 12:17 ET (17:17 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","PALI"],"gpt_icon":0},{"id":"2595790365","title":"Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2595790365","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595790365?lang=en_us&edition=fundamental","pubTime":"2025-12-30 21:35","pubTimestamp":1767101700,"startTime":"0","endTime":"0","summary":"PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and fibrostenotic Crohn’s disease (FSCD) to address signifi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/30/3211395/0/en/Palisade-Bio-Announces-Granting-of-Japanese-Patent-Covering-Composition-of-Matter-for-Lead-Product-Candidate-PALI-2108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","IND","BK4007","BK4139"],"gpt_icon":0},{"id":"2595065735","title":"Palisade Bio Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2595065735","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595065735?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:37","pubTimestamp":1767019020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PALI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 29, 2025 09:37 ET (14:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2595780917","title":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2595780917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595780917?lang=en_us&edition=fundamental","pubTime":"2025-12-29 20:58","pubTimestamp":1767013115,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio Dec 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Expedia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nL4N3XZ0LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","LU2065170008.USD","LU0162691827.USD","BK4585","LU0320765646.SGD","LU2065169927.USD","BK4142","PRAX","IE00BFMHRM44.USD","LU1162221912.USD","BK4139","BK4566","LU0054578231.USD","MTN","BK4216","HAS","LU0109394709.USD","LU1829250122.USD","EXPE","BK4007","LU0320765992.SGD","LU0072461881.USD","LU2065171402.SGD","BK4588","BP","LU0889565916.HKD","PALI","LU2065171311.SGD","BK4190","FOLD"],"gpt_icon":0},{"id":"2595788246","title":"Palisade Bio Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595788246?lang=en_us&edition=fundamental","pubTime":"2025-12-29 16:34","pubTimestamp":1766997288,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XY00J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2588591056","title":"BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec","url":"https://stock-news.laohu8.com/highlight/detail?id=2588591056","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588591056?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:46","pubTimestamp":1764683201,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James IzanecDec 2 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO STRENGTHENS CLINICAL LEADERSHIP TEAM WITH APPOINTMENT OF ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUACCYRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2588056593","title":"Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056593","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056593?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:45","pubTimestamp":1764683100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUACCYRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2582998103","title":"Palisade Bio price target raised to $8 from $2 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2582998103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582998103?lang=en_us&edition=fundamental","pubTime":"2025-11-12 01:45","pubTimestamp":1762883132,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm conte...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palisade-bio-price-target-raised-to-8-from-2-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palisade-bio-price-target-raised-to-8-from-2-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2581881099","title":"Palisade Bio Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881099","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881099?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:02","pubTimestamp":1762527739,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc  expected to post a loss of27cents a share - Earnings Preview Palisade Bio Inc PALI.OQ PALI.O is expected to  show no change in quarterly revenue when it reports  results on November ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ22T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2579011901","title":"Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579011901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579011901?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:36","pubTimestamp":1761744993,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc. has announced that it will hold a virtual Special Meeting of Stockholders on December 3, 2025. The meeting will be conducted online via live webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9J5h7M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2578213954","title":"BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2578213954","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578213954?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:49","pubTimestamp":1761655761,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical OperationsPalisade Bio Inc PALI.O:PALISADE BIO APPOINTS SHARON SKARE AS VICE PRESIDENT, GLOBAL HEAD OF CLINICAL OPERATIONSSource text: ID:nGNX1tfntPFurther company coverage: PALI.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA62TNVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2577889455","title":"Palisade Bio Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577889455","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577889455?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:49","pubTimestamp":1761000574,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc. held its annual meeting of stockholders on October 17, 2025. Stockholders elected three directors to the board. The selection of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. An amendment to the Amended and Restated Certificate of Incorporation to allow for a reverse stock split at a ratio between 1-for-5 and 1-for-50, at the discretion of the board of directors, was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Oc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL5Sg05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4139","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.palisadebio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0328},{"period":"3month","weight":0.1595},{"period":"6month","weight":0.7027},{"period":"1year","weight":0.277},{"period":"ytd","weight":-0.1957}],"compareEarnings":[{"period":"1week","weight":-0.0233},{"period":"1month","weight":-0.0044},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.068},{"period":"1year","weight":0.1339},{"period":"ytd","weight":-0.0064}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.011585},{"month":2,"riseRate":0.421053,"avgChangeRate":-0.042764},{"month":3,"riseRate":0.473684,"avgChangeRate":0.009436},{"month":4,"riseRate":0.421053,"avgChangeRate":-0.042784},{"month":5,"riseRate":0.263158,"avgChangeRate":-0.085738},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.050282},{"month":7,"riseRate":0.421053,"avgChangeRate":-0.087061},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.088321},{"month":9,"riseRate":0.526316,"avgChangeRate":0.073462},{"month":10,"riseRate":0.210526,"avgChangeRate":-0.030579},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.001568},{"month":12,"riseRate":0.473684,"avgChangeRate":0.019348}],"exchange":"NASDAQ","name":"Palisade Bio Inc.","nameEN":"Palisade Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palisade Bio Inc.,PALI,Palisade Bio Inc.股票,Palisade Bio Inc.股票老虎,Palisade Bio Inc.股票老虎国际,Palisade Bio Inc.行情,Palisade Bio Inc.股票行情,Palisade Bio Inc.股价,Palisade Bio Inc.股市,Palisade Bio Inc.股票价格,Palisade Bio Inc.股票交易,Palisade Bio Inc.股票购买,Palisade Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction